{
    "id": 3793,
    "fullName": "KDR amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "KDR (VEGFR2) amplification indicates an increased number of copies of the KDR (VEGFR2) gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3791,
        "geneSymbol": "KDR",
        "terms": [
            "KDR",
            "CD309",
            "FLK1",
            "VEGFR",
            "VEGFR2"
        ]
    },
    "variant": "amp",
    "createDate": "03/16/2015",
    "updateDate": "11/09/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6035,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial, treatment with Caprelsa (vandetanib) did not correlate with an improved PFS, OS, or objective response rate in non-small cell lung carcinoma patients harboring a KDR amplification nor did it inhibit cell proliferation of the KDR amplified archived tumor cells in culture (PMID: 26578684).",
            "molecularProfile": {
                "id": 3601,
                "profileName": "KDR amp"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5251,
                    "pubMedId": 26578684,
                    "title": "KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26578684"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16628,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with angiosarcoma harboring KDR (VEGFR2) and FLT4 (VEGFR3) amplification developed progressive disease while on Nexavar (sorafenib) teatment (PMID: 27160228).",
            "molecularProfile": {
                "id": 23076,
                "profileName": "FLT4 amp KDR amp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1816,
                "name": "angiosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5507,
                    "pubMedId": 27160228,
                    "title": "Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27160228"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6244,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with angiosarcoma harboring KDR (VEGFR2) and FLT4 (VEGFR3) amplification achieved stable disease for six months following treatment with Votrient (pazopanib) (PMID: 27160228).",
            "molecularProfile": {
                "id": 23076,
                "profileName": "FLT4 amp KDR amp"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 1816,
                "name": "angiosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5507,
                    "pubMedId": 27160228,
                    "title": "Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27160228"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14608,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of KIT, KDR, and PDGFRA (PMID: 29636358).",
            "molecularProfile": {
                "id": 30337,
                "profileName": "ROS1 fusion KDR amp KIT amp PDGFRA amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11739,
                    "pubMedId": 29636358,
                    "title": "Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29636358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3601,
            "profileName": "KDR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23076,
            "profileName": "FLT4 amp KDR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30337,
            "profileName": "ROS1 fusion KDR amp KIT amp PDGFRA amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}